Steve Potts, OncoMyx CEO
December 8, 2021 09:03 AM ESTUpdated December 9, 12:11 PM
Deals
Manufacturing

Biotech up­start gets $50M to test new virus-based ther­a­pies against sol­id tu­mors

Josh Sullivan

The team at On­coMyx is try­ing to lever­age one ther­a­peu­tic to treat sev­er­al forms of can­cer, us­ing the Myx­o­ma virus. Wednes­day, it an­nounced the clos­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times